CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Richard Lindahl

Profile

Richard Lindahl

Chief Financial Officer, Emergent BioSolutions Inc.

Leaving, effective January 1, 2027. First published here October 28, 2026; built from records as of October 28, 2026.

Richard Lindahl is leaving the chief financial officer seat at Emergent BioSolutions Inc.: the company's filing of October 16, 2026 gives January 1, 2027 as the effective date.1 The same filing names Frank Vargo as the successor, on an interim basis.1

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Emergent BioSolutions Inc. (EBS)
Pharmaceutical Preparations
Not statedLeaving, effective January 1, 20271

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. January 1, 2027takes effect

    Emergent BioSolutions Inc. named Frank Vargo to succeed Richard Lindahl on an interim basis, effective January 1, 2027. Profile of Frank Vargo.

    [1] Filing by Emergent BioSolutions Inc., filed with the SEC on October 16, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, Emergent BioSolutions Inc.. U.S. Securities and Exchange Commission, EDGAR, filed October 16, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Richard Lindahl wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.